Skip to main content

Table 1 Characteristics of nanocomposite formulations (Mean ± SD, n = 3)

From: Enhanced oral delivery of insulin via the colon-targeted nanocomposite system of organoclay/glycol chitosan/Eudragit®S100

Formulation

Size (nm)

PDI

Zeta-potential (mV)

EE (%)

AC-Ins

192 ± 8.20

0.20 ± 0.01

− 14.0 ± 4.41

97.6 ± 1.20

GAC-Ins

319 ± 9.42

0.46 ± 0.02

15.6 ± 2.31

90.7 ± 3.14

EGAC-Ins

412 ± 10.4

0.32 ± 0.02

− 20.6 ± 0.76

90.3 ± 1.06